Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | B4GALT1 | P15291 | 4/20 | 0.46 |
| ▸ | KRAS | P01116 | 2/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 8/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.40 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25890797 | 1.00 | B4GALT1 (0.46) | B4GALT1KRASP2RY14P2RY2P2RY6 | |
| SCHEMBL25893057 | 0.95 | B4GALT1 (0.46) | B4GALT1KRASP2RY14P2RY2P2RY6 | |
| SCHEMBL25893131 | 0.95 | B4GALT1 (0.46) | B4GALT1KRASP2RY14P2RY2P2RY6 | |
| SCHEMBL25893034 | 0.95 | B4GALT1 (0.46) | B4GALT1KRASP2RY14P2RY2P2RY6 | |
| SCHEMBL25891098 | 0.90 | KRAS (0.49) | B4GALT1KRASP2RY2P2RY6P2RY4 | |
| SCHEMBL25891103 | 0.90 | KRAS (0.49) | B4GALT1KRASP2RY2P2RY6P2RY4 | |
| SCHEMBL25890764 | 0.90 | KRAS (0.49) | B4GALT1KRASP2RY2P2RY6P2RY4 | |
| SCHEMBL25890775 | 0.90 | KRAS (0.49) | B4GALT1KRASP2RY2P2RY6P2RY4 | |
| SCHEMBL25962155 | 0.89 | KRAS (0.57) | KRASP2RY2P2RY6P2RY4FUT5 | |
| SCHEMBL25964112 | 0.89 | KRAS (0.57) | KRASP2RY2P2RY6P2RY4FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | FUT5, FUT6, SIGLEC7 | B4GALT1 41/4885KRAS 4257/4885P2RY14 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.